HuR has emerged as an attractive drug target for cancer therapy (24), and our works verified that SNHG12 could target HuR, thus regulating many mRNAs associated with cancer progression, which is meaningful and helpful for the development of drugs targeting HuR. Here, ELAVL1 is linked to cancer.